Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28008248 | 0.87 | TSHR (0.64) | TSHRNPC1MAPTFAAHPTPRC | |
| SCHEMBL132139 | 0.84 | NPC1 (0.46) | NPC1MAPTALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL126148 | 0.84 | NPC1 (0.55) | TSHRNPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6702666 | 0.82 | TSHR (0.56) | TSHRNPC1MAPTPTPRCPTPN1 | |
| SCHEMBL18601228 | 0.81 | NPC1 (0.52) | TSHRNPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL11525397 | 0.81 | ALDH1A1 (0.58) | TSHRNPC1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL22087977 | 0.80 | TSHR (0.58) | TSHRNPC1MAPTFAAHALDH1A1 | |
| SCHEMBL53331 | 0.80 | PPID (0.49) | TSHRNPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL7430396 | 0.80 | TSHR (0.62) | TSHRNPC1MAPTALDH1A1RAB9A | |
| SCHEMBL9622282 | 0.79 | NPC1 (0.52) | TSHRNPC1MAPTPTPRCPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019002407-A1 | PROCESS FOR THE PREPARATION OF TIPIRACIL HYDROCHLORIDE | AMNEAL PHARMACEUTICALS COMPANY GMBH (CH) | 2019-01-03 | — | — | WO | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| CN-101374844-B | Pyrrolopyridazinone compound | UBE INDUSTRIES | 2012-10-24 | — | — | CN | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101374844-A | Pyrrolopyridazinone compound | UBE INDUSTRIES (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1277748-B1 | Process for producing optically active y-Butyrolactone | TAKASAGO PERFUMERY CO LTD (JP) | 2004-04-21 | — | — | EP | disclosed |
| EP-1403262-A1 | Process for producing optically active alpha butyrolactone | Takasago International Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6608214-B2 | Hydrogenating optically active 4-substituted oxy-3-hydroxy-butyrate followed by simultaneous deprotection and ring closure; economic and efficient synthesis | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-08-19 | — | — | US | disclosed |
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1277748-A1 | Process for producing optically active y-Butyrolactone | Takasago International Corporation (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-4421922-A | Process for the production of tetronic acid | LONZA LTD. (CH) | 1983-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | HSD17B10, HSD17B1, HSD17B12 | TSHR 4191/4885NPC1 4560/4885MAPT 2971/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | TSHR 1420/4885NPC1 1907/4885MAPT 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.